Global Pharmaceutical Policy
Show Less

Global Pharmaceutical Policy

Ensuring Medicines for Tomorrow’s World

Frederick M. Abbott and Graham Dukes

Pharmaceuticals play a central role in health care throughout the world. The pharmaceutical industry is beset with difficulties as increasing research and development expenditure yields fewer new treatments. Public and private budgets strain under the weight of high prices and limited access. The world’s poor see little effort to address diseases prevalent in less affluent societies, while the world’s wealthy are overusing prescription drugs, risking their health and wasting resources.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 7: Regulation and the Role of the Courts

Frederick M. Abbott and Graham Dukes


The role which governments have increasingly assumed of protecting the public interest in the field of medicines in no way obviates the role of the public in defending its own interests by exerting pressure through representative organizations or the media, or more importantly by taking legal action in the civil courts where necessary. Such action may be taken against various parties such as physicians, pharmacists, hospitals or public health authorities. The discussion that follows is primarily concerned with legal action brought against the pharmaceutical trade or industry, on grounds that may range from the publication of misleading advertisements to the sale of dangerous products. In some matters there is also a role for administrative sanctions and for the institution of criminal proceedings by the regulatory agency itself. From the point of view of public policy, civil litigation in this field may at its best be seen as complementing the protective role of the state. As Australian John Braithwaite concluded, surveying the scene in depth as long ago as 1984: In most countries, but especially the United States, product liability law rather than criminal law has provided most of the deterrence against corporate crime in the pharmaceutical industry. Compensation, not deterrence, is the recognized function of product liability law. Yet the conclusion from my interviews was that pharmaceutical executives report fear of product-liability suits as a reason for obeying the Food, Drug and Cosmetic Act of immensely greater importance than fear of criminal prosecution or any other regulatory action.1 The state...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.